Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab, PMID: 27723281
The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity, PMID: 23684423
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?, PMID: 28765121
Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors, PMID: 23268367
Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma, PMID: 27350068
Further thoughts about the ILLUMINATE studies of tabalumab in SLE, PMID: 26530320
Emerging B-Cell Therapies in Systemic Lupus Erythematosus, PMID: 33488082
Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial, PMID: 23359344
Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus, PMID: 29426575
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma, PMID: 28005265
Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus, PMID: 26648084
Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study, PMID: 25873635
The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials, PMID: 27220348
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma, PMID: 27287072
Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study, PMID: 26535134
Developmental Toxicity and Fertility Assessment in Rabbits with Tabalumab: A Human IgG4 Monoclonal Antibody, PMID: 26195315
Efficacy and Safety of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population: Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O), PMID: 26203826
A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate, PMID: 23599435
Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation, PMID: 26780484
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study, PMID: 26338095
Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor, PMID: 25258549
Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluations, PMID: 25585959
A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis, PMID: 25168268
Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study, PMID: 27471815
Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples, PMID: 23625979
An Enhanced Pre- and Postnatal Development Study in Cynomolgus Monkeys with Tabalumab: A Human IgG4 Monoclonal Antibody, PMID: 26195230
eLetter: Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors by M Genovese, PMID: 23396663
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study, PMID: 26293163
Emerging antibodies for the treatment of multiple myeloma, PMID: 27195659
Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis, PMID: 31617269
Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis, PMID: 31910414
Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE), PMID: 28164726
B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?, PMID: 25723853
Update on clinical trials in systemic lupus erythematosus, PMID: 27314466
B-cell survival factors in autoimmune rheumatic disorders, PMID: 26288664
B-cell targeted therapeutics in clinical development, PMID: 23566679
Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?, PMID: 22547203
The efficacy of novel B cell biologics as the future of SLE treatment: a review, PMID: 25149393
The safety and efficacy of biologic agents in treatment of systemic lupus erythematosus: A network meta-analysis, PMID: 31777515
Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus, PMID: 24521424
B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases, PMID: 27655102
Treating multiple sclerosis with monoclonal antibodies: a 2013 update, PMID: 23448220
Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty?, PMID: 26590173
Which are the antibodies to watch in 2013?, PMID: 23254906
Antibodies to watch in 2013: Mid-year update, PMID: 23727858
Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis, PMID: 28673504
Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis, PMID: 22171583
Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease, PMID: 31181988
A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus, PMID: 31790472
[State of the art treatment of progressive or refractory multiple myeloma], PMID: 25268212
Current status of BAFF targeting immunotherapy in B-cell neoplasm., PMID:39222149
Anti-B-Cell-Activating Factor (BAFF) Therapy: A Novel Addition to Autoimmune Disease Management and Potential for Immunomodulatory Therapy in Warm Autoimmune Hemolytic Anemia., PMID:39062171
Analysis of transcriptomic features reveals molecular endotypes of SLE with clinical implications., PMID:37845772
Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE)., PMID:37807057
Efficacy and Safety of New B Cell-Targeted Biologic Agent for the Treatment of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis., PMID:37510963
Advances in natural products and antibody drugs for SLE: new therapeutic ideas., PMID:37492083
Distinct binding mode of BAFF antagonist antibodies belimumab and tabalumab, analyzed by computer simulation., PMID:36063219
External Validation of the Lupus Multivariable Outcome Score for Systemic Lupus Erythematosus Trials., PMID:35962577
Scoring personalized molecular portraits identify Systemic Lupus Erythematosus subtypes and predict individualized drug responses, symptomatology and disease progression., PMID:35947992
What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?, PMID:35794296
[Advances of using antibody against B cell activating factor for treatment of autoimmune diseases]., PMID:35355463
Emerging B-Cell Therapies in Systemic Lupus Erythematosus., PMID:33488082
Current Understanding and Unknown Aspects of the Treatment of Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Opportunities for Future Studies., PMID:32228425
Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis., PMID:31910414
A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus., PMID:31790472
The safety and efficacy of biologic agents in treatment of systemic lupus erythematosus: A network meta-analysis., PMID:31777515
Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis., PMID:31617269
Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease., PMID:31181988
Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus., PMID:29426575
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?, PMID:28765121
Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis., PMID:28673504
Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)., PMID:28164726
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma., PMID:28005265
The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials., PMID:27220348
Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab., PMID:27723281
Biotherapies in systemic lupus erythematosus: New targets., PMID:27663753
B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases., PMID:27655102
Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study., PMID:27471815
Unexpected Potency Differences between B-Cell-Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound., PMID:27440419
Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma., PMID:27350068
Update on clinical trials in systemic lupus erythematosus., PMID:27314466
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma., PMID:27287072
Emerging antibodies for the treatment of multiple myeloma., PMID:27195659
Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation., PMID:26780484
Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus., PMID:26648084
BAFF inhibition does not significantly impair immunization responses in patients with rheumatoid arthritis., PMID:26621128
Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty?, PMID:26590173
Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study., PMID:26535134
Further thoughts about the ILLUMINATE studies of tabalumab in SLE., PMID:26530320
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study., PMID:26338095
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study., PMID:26293163
B-cell survival factors in autoimmune rheumatic disorders., PMID:26288664
Efficacy and Safety of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population: Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O)., PMID:26203826
Developmental Toxicity and Fertility Assessment in Rabbits with Tabalumab: A Human IgG4 Monoclonal Antibody., PMID:26195315
An Enhanced Pre- and Postnatal Development Study in Cynomolgus Monkeys with Tabalumab: A Human IgG4 Monoclonal Antibody., PMID:26195230
Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study., PMID:25873635
B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?, PMID:25723853
[Therapeutic monoclonal antibodies against multiple myeloma]., PMID:25626316
Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluations., PMID:25585959
[State of the art treatment of progressive or refractory multiple myeloma]., PMID:25268212
For research use only. Not for human or drug use.
